Notably, Pyrazofurin, when combined with trametinib (a MAP kinase inhibitor), effectively inhibits the growth of CRC cells with elevated DKC1 expression in vitro and in vivo, suggesting potential applications in DKC1‐overexpressing cancers.112. The gene discussed is DKC1; the disease is cancer.